Italy Liver Diseases Therapeutics Market Report 2022 to 2030

Italy Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Italy Liver Disease Therapeutics market will reach a value of $831 Mn from $554 Mn in 2022, growing at a CAGR of 5.2% during 2022-2030. Liver Disease Therapeutics in Italy is dominated by a few domestic pharmaceutical companies such as Esaote, Chiesi Group, and Dompé. The Liver Disease Therapeutics market in Italy is segmented into different types of disease and different therapy types. Some of the major factors affecting the Italy Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10ITPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Italy AUTHOR: Dr. Vishwa Modhia

Buy Now

Italy Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Italy Liver Disease Therapeutics market will reach a value of $831 Mn from $554 Mn in 2022, growing at a CAGR of 5.2% during 2022-2030.

Italy is a high-income, developed country located in Southern Europe comprising the boot-shaped Italian peninsula and a number of islands including Sicily and Sardinia. Hepatitis B and C are also major causes of liver disease in Italy. It is estimated that roughly 1 Mn persons in Italy have chronic hepatitis B or C. The Italian government has also created a nationwide NAFLD prevention initiative. Public education campaigns and initiatives to promote healthy diet and physical activity are part of the programme.

According to the latest WHO data published in 2020 Liver Disease Deaths in Italy reached 5,559 or 1.02% of total deaths. The age-adjusted Death Rate is 3.92 per 100,000 population ranks Italy 171^st in the world. Italy's government spent 12.8 % of its GDP on healthcare in 2020.

Italy Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Alcohol-related liver disease is the most frequent type of liver disease in Italy, accounting for around 60% of all liver disease cases, according to the Italian Association for the Study of the Liver (AISF). In Italy, liver disease is a leading cause of death. Over 39,000 people were hospitalised in Italy for liver illness in 2019, with an average hospital stay of 8 days. Liver illnesses accounted for 3.5 % of all fatalities in Italy in 2019. The industrial industry is still highly respected in Italy. These aspects could boost Italy's Liver Disease Therapeutics market.

Market Restraints

Even though Italy is a developed country with a strong healthcare system, financing for specialised research efforts is limited. This can make it challenging to get the necessary funds for research and development of new liver disease treatments. These factors may deter new entrants into the Italy Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Chiesi Group: Chiesi Group is an Italian pharmaceutical company that is involved in the development and commercialization of a range of liver disease therapeutics, including treatments for primary biliary cholangitis (PBC) and portal hypertension
Dompé Farmaceutici: Dompé Farmaceutici is an Italian pharmaceutical company that is focused on the development and commercialization of treatments for a range of diseases, including liver diseases such as hepatitis C
Esaote: Esaote is an Italian medical device company that specializes in the development of non-invasive diagnostic tools for liver diseases, including FibroScan, which is used to measure liver stiffness
MolMed: MolMed is an Italian biotech company that is focused on the development of cell and gene therapies for a range of diseases, including liver diseases such as liver cancer

Healthcare Policies and Reimbursement Scenarios

In terms of regulations, the Italian Medicines Agency (AIFA) is responsible for approving drugs for the Italian market, ensuring their safety and efficacy, and setting reimbursement prices. The agency works closely with the European Medicines Agency (EMA) to ensure that the drugs approved in Italy meet the standards of the European Union. Regarding reimbursements, the Italian healthcare system operates on a regional basis, and each region has its own reimbursement system. However, the national government provides guidelines for reimbursement rates for drugs and medical treatments, including liver disease therapeutics.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.